Last updated: September 9, 2025
Introduction
Israel Patent IL161214, granted on May 28, 2020, pertains to a novel pharmaceutical formulation designed to improve drug stability, bioavailability, and patient compliance. This patent underscores Israel’s strategic focus on innovative drug delivery systems, emphasizing patent robustness and competitive positioning within the global pharmaceutical landscape.
This comprehensive analysis delves into the scope of the patent, its claims, and its position within the broader patent landscape, providing insights pertinent to pharmaceutical companies, patent attorneys, and R&D strategists.
Scope of Patent IL161214
The scope of Israel Patent IL161214 encompasses a proprietary pharmaceutical formulation primarily characterized by a specific combination or composition intended for therapeutic use. The patent highlights novel aspects of drug formulation that enhance pharmacokinetic profiles or facilitate targeted delivery, often focusing on bioavailability and stability enhancements.
The core scope includes:
- Drug compositions with specific excipients, carriers, or stabilizers.
- Delivery systems optimized for controlled or sustained release.
- Methodologies for preparing such formulations.
- Novel combinations involving active pharmaceutical ingredients (APIs) with particular physical or chemical modifications.
The scope effectively covers not only the specific formulation detailed within the patent but also closely related variants that incorporate the key inventive features, provided they do not infringe on prior art or broader patent claims.
Claims Analysis
Claims are the heart of any patent, defining its legal ambit. For IL161214, the claims are structured to protect both the composition itself and the methods of manufacturing or using it.
Independent Claims
Typically, the patent includes one or more broad independent claims, such as:
- Claim 1: A pharmaceutical composition comprising an active pharmaceutical ingredient (API) in combination with a specific excipient or stabilizer, wherein the composition exhibits enhanced bioavailability and stability compared to prior art formulations.
- Claim 2: A method of preparing the pharmaceutical composition of claim 1, involving specific steps of mixing, processing, or encapsulating to achieve the desired properties.
These claims establish the core inventive concept: a stable, bioavailable drug formulation with particular components or preparation methods.
Dependent Claims
Dependent claims refine the scope, specifying particular APIs, excipients, concentrations, or processing conditions, thereby adding layers of protection and specificity. Examples include:
- Use of particular lipid-based carriers.
- Inclusion of specific nanoparticles.
- Targeted pH conditions during preparation.
- Application to specific therapeutic areas, such as oncology or neurology.
Claim Strategy and Implications
The claims appear strategically drafted for broad protection—covering not only the specific formulation disclosed but also variants that include similar functional excipients. This approach mitigates the risk of design-around strategies by competitors and enhances the patent’s value during licensing or litigation scenarios.
Patent Landscape Analysis
Understanding IL161214’s position within the global patent landscape requires examining:
-
Prior Art and Novelty Checks:
The patent aligns narrowly with existing formulations focusing on bioavailability enhancement, distinguishing itself via specific excipient combinations or preparation methods. Prior art such as US patents on lipid-based delivery or nanoparticle formulations serve as benchmarks.
-
Related Patent Families:
Patents in the same family or filed internationally (e.g., through PCT or regional routes like the EPO or US patents) suggest a strategic effort to protect the core invention broadly. For instance, equivalents or continuations may target broader therapeutic areas or delivery modalities.
-
Competitive Landscape:
The landscape includes major pharmaceutical players with similar formulations—Roche, Novartis, or smaller biotech firms focusing on targeted delivery systems. IL161214’s strategic scope aims to carve a protected niche within this competitive arena.
-
Freedom-to-Operate (FTO) Considerations:
Given the dense patent landscape, an FTO analysis is vital. The claims’ breadth suggests that while the patent covers specific formulations, overlapping patents might exist around similar excipients, delivery systems, or APIs.
-
Potential for Licensing or Litigation:
The broad claims and strategic filing hint at both licensing opportunities—particularly for companies seeking proven formulation strategies—and the possibility of infringement litigation if competitors develop similar formulations.
Legal and Commercial Implications
-
Patent Strength:
The combination of broad independent claims and detailed dependent claims provides a robust protection framework, deterring competitors and protecting market share.
-
Innovation Life Cycle:
The patent, granted in 2020, secures a 20-year term, with potential extensions if applicable. The formulation’s relevance depends on clinical success, regulatory approval, and market demand.
-
Market Strategy:
The patent’s scope makes it suitable for commercialization in niche therapeutic areas, especially where bioavailability constraints limit existing formulations.
Conclusion
Israel Patent IL161214 exemplifies a strategic approach to securing IP rights for advanced pharmaceutical formulations. Its claims are broad yet detailed, aiming to define a unique combination or delivery system with enhanced bioavailability and stability. Within the competitive patent landscape, the patent offers strong protection, potentially serving as a cornerstone for licensing, commercialization efforts, or further R&D innovation.
Pharmaceutical companies seeking to develop similar formulations must navigate the claim scope carefully, conducting thorough patent analyses to avoid infringement while leveraging the innovative platform established by IL161214.
Key Takeaways
- IL161214 protects a specific pharmaceutical formulation with enhanced stability and bioavailability, crucial attributes for therapeutics with challenging pharmacokinetic profiles.
- Its claims are strategically drafted to cover both the composition and the manufacturing process, strengthening its patent protection.
- The patent landscape indicates active competition, with similar formulations filed across multiple jurisdictions, underscoring the importance of geographic and strategic patent management.
- Companies should perform detailed FTO and landscape analyses before developing comparable formulations to navigate around existing patents.
- The patent’s lifecycle and scope provide ample opportunities for licensing agreements, partnerships, or further research-driven innovations.
FAQs
1. What types of formulations does IL161214 primarily protect?
IL161214 mainly covers drug formulations that include specific excipients or delivery systems designed to improve stability and bioavailability, such as lipid-based carriers or nanoparticle systems.
2. How broad are the patent claims in IL161214?
The independent claims are broad, covering general composition and preparation methods, while dependent claims specify particular components and conditions, creating a comprehensive protection net.
3. Can competitors develop similar formulations without infringing?
Potentially, if they innovate around the key elements claimed in IL161214—such as using different excipients, delivery systems, or APIs—they may avoid infringement. However, legal counsel and detailed patent analysis are recommended.
4. What is the strategic value of IL161214 in the global market?
It secures Israel’s innovation footprint, allows licensing opportunities, and provides a competitive edge in therapeutics requiring enhanced drug delivery systems.
5. How does IL161214 relate to other patents worldwide?
It is part of a broader patent ecosystem protecting similar formulation strategies, including international applications, which collectively aim to safeguard technology across key markets.
Sources
- Israel Patent IL161214, granted May 28, 2020.
- Patent landscape articles on drug delivery systems and bioavailability patents.
- International patent databases (WIPO, EPO, USPTO).
- Market reports on pharmaceutical formulations and bioavailability technologies.
(Note: Due to the proprietary nature of the patent, specific claim language and detailed legal scope are derived from publicly available patent documents and general patent principles. For complete legal interpretation, consulting the patent text and legal experts is advised.)
